Change in curve changed the ratio of Cmax [Bioanalytics]

posted by Compliance – India, 2015-03-25 13:13 (3717 d 07:22 ago) – Posting: # 14616
Views: 12,091

Dear Dr_Dan,

❝ So the difference in Cmax ratio is due to the different number of test/reference comparisons since you now have additional profiles which were not available before due to the poor sensitivity of the first method, right?


Yes.

❝ In this case the first method is not appropriate to evaluate the study.


A product in which we are working having issue with itself. actually it is not possible to get the consistent performance in healthy subject. it is locally acting and if we need to get success then the patient is the only option. Actual suggested LLOQ in SBOA is 5 ng/ml which was used at the initiation of the study and based on the experience of each repeated study we have revised the LLOQ.

According to the European BE guidelines the lower limit of quantitation should be 1/20 of Cmax or lower, as pre-dose concentrations should be detectable at 5% of Cmax or lower.

we are working on Meselamine and conventional approach could not work.

Regards,

Compliance

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
59 visitors (0 registered, 59 guests [including 12 identified bots]).
Forum time: 21:36 CEST (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5